Evidence map›Paper›PMID 33888034›Full record

ReviewExpert review of gastroenterology & hepatology2021

Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Antonio Cigliano, Xin Chen, Diego F Calvisi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Antonio CiglianoDepartment of Medical, Surgery and Experimental Sciences, Division of Experimental Pathology and Oncology, University of Sassari, Sassari Italy.ORCID https://orcid.org/0000-0002-6408-3613
Xin ChenDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
Diego F CalvisiInstitute of Pathology, University of Regensburg, Regensburg, Germany.
University of California, San Francisco · USUniversity of Regensburg · DEUniversity of Sassari · IT

Funding

Role of Cancer-Associated Fibroblasts in CholangiocarcinomaR01CA228483 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHEN, XIN, SCHWABE, ROBERT F. · 2018 to 2022
$3.1M
Towards a Comprehensive Developmental Model of Substance Use DisordersR01DA019606 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI OLFSON, MARK · 2006 to 2016
$2.6M
Prevalence, Predictors, and Consequences of Alcohol Use from Childhood to MidlifeR01AA019606 · NIAAA · PENNSYLVANIA STATE UNIVERSITY, THE · PI MAGGS, JENNIFER L · 2011 to 2014
$2.2M
Signaling cascades in cholangiocarcinoma developmentR01CA190606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA190606NCI NIH HHS R01 CA228483NIAAA NIH HHS R01 AA019606NIDA NIH HHS R01 DA019606
6 · The paper itself

Abstract

areas coveredThis review provides an overview regarding the current scenario and knowledge of the CCA genomic landscape and the potentially actionable molecular aberrations in each CCA subtype. EXPERT OPINION: The establishment and advances of high-throughput methodologies applied to genetic and epigenetic profiling are changing many cancer types' therapeutic landscape , including CCA.The large body of data generated must be interpreted appropriately and eventually implemented in clinical practice. The following advancements toward precision medicine in CCA management will require designing better clinical trials with improved methods to stratify biliary tumor patients.

Indexed as

Bile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaCombined Modality TherapyEpigenesis, GeneticGene Expression ProfilingHumansMolecular Targeted TherapyMutationPrecancerous ConditionsRisk FactorsBiomarkers, TumorCholangiocarcinomadriver mutationsepigeneticsgenomic landscapemolecular pathogenesismolecular profilingnext-generation sequencingprecision medicinepredictive biomarkerstargeted therapies

Identifiers

PMID33888034
PMCPMC8173760
OpenAlexW3155656086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.